On the Safety of 5-[125I]IODO-2'-Deoxyuridlne: Preclinical evaluation in swine

Authors

  • Janina Baranowska-Kortylewicz Departments of Radiology (Nuclear Medicine) and Radiation Oncology, J. Bruce Henriksen Laboratories, Omaha, Nebraska, USA
  • Glenn V. Dalrymple Departments of Radiology (Nuclear Medicine) and Radiation Oncology, J. Bruce Henriksen Laboratories, Omaha, Nebraska, USA
  • Katherine A. Harrison Departments of Radiology (Nuclear Medicine) and Radiation Oncology, J. Bruce Henriksen Laboratories, Omaha, Nebraska, USA
  • Karen P. Holdeman Departments of Radiology (Nuclear Medicine) and Radiation Oncology, J. Bruce Henriksen Laboratories, Omaha, Nebraska, USA
  • J. Graham Sharp Department of Cell Biology and Anatomy, J. Bruce Henriksen Laboratories, Omaha, Nebraska, USA
  • Samuel M. Cohen Department of Pathology and Microbiology, J. Bruce Henriksen Laboratories, Omaha, Nebraska, USA
  • Robert P. Lieberman Departments of Radiology (Nuclear Medicine) and Radiation Oncology, J. Bruce Henriksen Laboratories, Omaha, Nebraska, USA
  • Martin H. Schneiderman Departments of Radiology (Nuclear Medicine) and Radiation Oncology, J. Bruce Henriksen Laboratories, Omaha, Nebraska, USA
  • Sydney R. Clausen Departments of Radiology (Nuclear Medicine) and Radiation Oncology, J. Bruce Henriksen Laboratories, Omaha, Nebraska, USA
  • Debra Hoffman Departments of Radiology (Nuclear Medicine) and Radiation Oncology, J. Bruce Henriksen Laboratories, Omaha, Nebraska, USA
  • Jing Lai Departments of Radiology (Nuclear Medicine) and Radiation Oncology, J. Bruce Henriksen Laboratories, Omaha, Nebraska, USA
  • G. Sue Schneiderman Departments of Radiology (Nuclear Medicine) and Radiation Oncology, J. Bruce Henriksen Laboratories, Omaha, Nebraska, USA
  • Lynn Helseth Departments of Radiology (Nuclear Medicine) and Radiation Oncology, J. Bruce Henriksen Laboratories, Omaha, Nebraska, USA

DOI:

https://doi.org/10.3109/02841869609104047

Abstract

To increase tumor incorporation and minimize hepatic degradation of radio-IUdR, compartmental administration routes are being considered as an alternative to intravenous (i. v.) injections. Although there are significant data on the biodistribution and some reports on radiotoxicity of i. v.-administered 125IUdR, similar results for other routes of delivery are not available. We have undertaken a series of experiments intended to examine radiation effects of 125IUdR after intravesical (3 swine; eight 3 mCi doses at 4-day intervals), intracarotid (3 swine; two 10 mCi doses at 2-week intervals), and intra-aortic (5 swine, single dose of 10 mCi) administration in a swine model. Liver, renal functions, and complete blood counts were monitored throughout the duration of the experiment. Pharmacokinetics, systemic distribution of radioactivity and metabolites were measured. The normal tissue 125IUdR uptake and histology were determined after necropsy. No adverse systemic effects were identified. Clinical observations, laboratory data, and necropsy results were within normal range.

Downloads

Download data is not yet available.

Downloads

Published

1996-01-01

How to Cite

Baranowska-Kortylewicz, J. ., Dalrymple, G. V. ., Harrison, K. A. ., Holdeman, K. P. ., Graham Sharp, J. ., Cohen, S. M. ., … Helseth, L. . (1996). On the Safety of 5-[125I]IODO-2’-Deoxyuridlne: Preclinical evaluation in swine. Acta Oncologica, 35(7), 925–933. https://doi.org/10.3109/02841869609104047